Method for Determining the Reliability of a Device for Measuring the Concentration of a Substance in Whole Blood, Method for Treating Whole Blood, Container and Kit

• US 20120301908A1
• Filed: 01/20/2011
• Published: 11/29/2012
• Est. Priority Date: 02/01/2010
• Status: Abandoned Application

• Current Assignee: Eurotrol B.V.
• Original Assignee: Eurotrol B.V.
• Inventors: Jungerius, Bart Johan, Huizing, Carolina Johanna, Maas, Bartholomeus Henricus Antonius
• Application Number:
  US13/576,595
• Publication Number:
  US 20120301908A1
• Time in Patent Office: Days
• US Class Current: 435/14
• CPC Class Codes: A61B 2560/0228 using calibration standards
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: G01N 2496/05 containing blood cells or plasma
• CPC Class Codes: G01N 33/96 involving blood or serum control standard

Abstract

The present invention pertains to the field of measuring the concentration of a substance in whole blood and relates to a method for determining the reliability of a device for measuring the concentration of a substance in whole blood, and to a method for treating whole blood, wherein a cell-free blood fraction enriched with said substance and a suspension of blood cells are stored separately from each other. The invention also relates to a container and to a kit.

Claims

1. A method for determining the reliability of a device for measuring the concentration of a substance in whole blood comprising the following successive steps:

a) mixing a separated, stored, cell-free blood fraction, selected from plasma and serum, and a suspension of blood cells, each separated from whole control blood, with a known amount of the substance being added to the cell-free blood fraction;

b) measuring, by means of the device, the concentration of the substance in the reconstituted whole control blood enriched with said substance in step a);

c) determining the reliability of the device on the basis of the difference between (i) the known concentration of the substance after step a) and (ii) the result of the measurement of the measurement of step b),

wherein said cell-free blood fraction and said suspension of blood cells are preferably stored at a temperature of 2-8°

C.

2. A method according to claim 1, wherein the cell-free blood fraction and the suspension of blood cells to be used in step (a) are obtained by centrifuging whole control blood and removing 5-90 volume percent of the cell-free blood fraction so as to obtain a suspension of blood cells, possible using one or more additives, wherein preferably 75-85 volume percent of the cell-free blood fraction is removed.

3. A method according to claim 2, wherein the haematocrit content of the suspension of blood cells is adjusted to 20-90, wherein preferably the haematocrit content is adjusted to 50-80 volume percent.

4. A method according to claim 1, wherein the whole control blood consists of mammalian blood, including human blood, preferably said blood is bovine blood or human blood.

5. A method according to claim 1, wherein either the suspension of blood cells from the control blood or the substance-enriched cell-free blood fraction is stored in a container, wherein the substance-enriched cell-free blood fraction or the suspension of blood cells, as the case may be, is preferably aseptically distributed over sterile bottles, wherein the container is preferably connected to a bottle containing the substance-enriched cell-free blood fraction or the suspension of blood cells prior to the mixing step.

6. A method according to claim 1, wherein the substance is added to the cell-free blood fraction in an amount such that a desired concentration of the substance in the sample is obtained after reconstitution of the cell-free blood fraction with an amount of the suspension of blood cells into a sample of whole control blood enriched with said substance, wherein preferably different concentrations of the substances are added to different samples of the cell-free blood fraction.

7. A method according to claim 1, wherein the substance is selected from the group consisting of metabolites, tracers for infectious diseases, toxicologically relevant substances and tracers therefor, preferably said substance is glucose.

13. A container which contains either a suspension of blood cells obtained from whole blood or a cell-free blood fraction enriched with the substance to be measured, which cell-free blood fraction or which suspension of blood cells has been obtained by using a method according to claim 1, wherein a bottle containing either the suspension of blood cells obtained from whole blood or the substance-enriched cell-free blood fraction obtained from said whole blood is connected to the container or to the supply part of the assembly.

14. A container according to claim 13, which container is an assembly comprising a dosing part and a supply part, wherein the dosing part contains either a suspension comprising blood cells obtained from whole blood or a cell-free blood fraction enriched with a substance to be measured, and wherein the metering part and the supply part are configured to cooperate with one another, such that a pressure chamber having a changeable volume is formed when the supply part and the dosing part are joined together, which pressure chamber functions to obtain a pumping action for mixing the suspension of blood cells with the cell-free blood fraction to be added or mixing the cell-free blood fraction with the suspension of blood cells to be added, as the case may be, which suspension and which cell-free blood fraction have been obtained by using a method according to claim 1.

15. A kit for determining the reliability of a device for measuring the concentration of a substance in whole blood, the kit comprises (i) at least one container containing either a suspension of blood cells of whole control blood or a cell-free blood fraction enriched with a substance to be measured, and (ii) at least one bottle containing cell-free blood fraction comprising a known concentration of the substance or the suspension of blood cells, and (iii) possibly instructions for mixing the cell-free blood fraction with the suspension of blood cells, in order to obtain one or more whole control blood samples, which suspension and which cell-free blood fraction have been obtained by using a method according to claim 1, and for measuring the concentration of the substance in the sample or the samples by means of the device for measuring the concentration of the substance in whole blood whose reliability is to be determined.

8. A method for treating whole blood comprising the following successive steps:

(a) centrifuging whole blood, with the possible use of one or more additives, so as to obtain a cell-free blood fraction selected from plasma or serum;

(b) removing 5-90 volume percent of the cell-free blood fraction, with the possible use of one or more additives, so as to obtain a suspension of blood cells;

(c) adding such an amount of a substance to be measured to the cell-free blood fraction that a desired concentration of the substance in the sample is obtained following the reconstitution into a whole blood sample of (i) the cell-free blood fraction enriched with said substance and (ii) an amount of the suspension of blood cells;

(d) storing the substance-enriched cell-free blood fraction and the suspension of blood cells separately from each other,

wherein preferably 75-85 volume percent of the cell-free blood fraction is removed in step (b), and wherein the cell-free blood fraction and the suspension of blood cells are preferably stored at a temperature of 2-8°

C.

9. A method according to claim 8, wherein the haematocrit content of the suspension of blood cells is adjusted to 20-90, wherein preferably the haematocrit content is adjusted to 50-80 volume percent.

10. A method according to claim 8, wherein the whole control blood consists of mammalian blood, including human blood, preferably said blood is bovine blood or human blood.

11. A method according to claim 8, wherein either the suspension of blood cells from the blood or the substance-enriched cell-free blood fraction is stored in a container, wherein container containing either the suspension of blood cells or the substance-enriched cell-free blood fraction is preferably connected to a bottle containing the substance-enriched cell-free blood fraction or the suspension of blood cells prior, which suspension or which cell-free blood fraction containing the substance is preferably aseptically distributed over sterile bottles.

12. A method according to claim 8, wherein the substance is selected from the group consisting of metabolites, tracers for infectious diseases, toxicologically relevant substances and tracers therefor, preferably said substance is glucose.